Drug Type Small molecule drug |
Synonyms Acotiamide, Acotiamide hydrochloride (USAN), Acotiamide hydrochloride hydrate (JAN) + [8] |
Action antagonists, inhibitors |
Mechanism A1R antagonists(Adenosine A1 receptor antagonists), AChE inhibitors(Acetylcholinesterase inhibitors), M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (25 Mar 2013), |
Regulation- |
Molecular FormulaC21H37ClN4O8S |
InChIKeyNPTDXIXCQCFGKC-UHFFFAOYSA-N |
CAS Registry773092-05-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D08838 | Acotiamide Hydrochloride Hydrate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Dyspepsia | Japan | 25 Mar 2013 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Postprandial distress syndrome | Phase 3 | Belgium | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Bulgaria | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Latvia | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Lithuania | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Romania | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Russia | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Slovakia | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Sweden | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | Ukraine | 01 Mar 2014 | |
| Postprandial distress syndrome | Phase 3 | United Kingdom | 01 Mar 2014 |
Phase 3 | - | ypxepbonba(fyryejclml) = hjyzlbqlrq qzumiezvtt (cvpxmcfked ) | Positive | 01 Jun 2012 | |||
Placebo | ypxepbonba(fyryejclml) = lpbsvsyhaw qzumiezvtt (cvpxmcfked ) |





